Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study)
PLOS One · 2025
DOI: 10.1371/journal.pone.0322621 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von Mitsuhiro Akiyama und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Methotrexate, Pyridines. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Filgotinib (FIL), a Janus kinase-1 preferential inhibitor, has been studied for its efficacy and safety in rheumatoid arthritis. The FINCH3 trial compared FIL monotherapy, FIL plus methotrexate (MTX) combination therapy, and MTX monotherapy in MTX-naïve patients. However, comparisons in patients with an inadequate response to MTX remain unclear. This study aims to evaluate the efficacy and safety of FIL plus MTX versus FIL monotherapy in patients with rheumatoid arthritis who have an inadequate response to MTX. Methods and analysis FAITHFUL ( F ilgotinib A dd-on versus sw IT c H to F ilgotinib in patients with rhe U matoid arthritis who inadequate L y responded to methotrexate) study is a phase IV multicenter, prospective, open-label, randomized controlled trial. Patients with a history of inadequate response to at least 8 weeks of MTX and moderate or high disease activity will be assessed for eligibility at 10 centers in Japan. A history of Janus kinase inhibitor use is an exclusion criterion, but prior use of biologic agents is not considered. Enrolled patients will be randomly assigned in a 1:1 ratio to either the group adding FIL (Add-on group) or the group switching to FIL monotherapy (Switch group). The target sample size is 120 participants. The primary endpoint is the change in DAS28-CRP from baseline to week 24, aiming to assess if the Switch group is non-inferior to the Add-on group. Safety will be evaluated by assessing the incidence of adverse events. Ethics and dissemination The study has received approval from the Certified Review Board of Keio University Hospital (N20230002) and adheres to the principles outlined in the Declaration of Helsinki and good clinical practice standards. Prior to enrollment, all participants provide written informed consent. The findings from this study are intended to be submitted for publication in relevant peer-reviewed journals.
Trial registration
The trial was registered at Japan Registry of Clinical Trials (jRCTs031230673).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
- Institute of Rheumatology, Miyazaki Zenjinkai Hospital, Miyazaki, Japan.
- Kaneko Internal Medicine Rheumatology Clinic, Kawaguchi, Japan.
- Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan.
- Department of Internal Medicine and Center for Arthritis and Rheumatic Disease, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan.
- Tohoku Medical and Pharmaceutical University, Division of Hematology and Rheumatology, Sendai, Japan.
ORCID-Profile: Mitsuhiro Akiyama, Tomonori Ishii
Zitieren
APA
Akiyama, M., Hidaka, T., Kaneko, M., Ito, S., Taguchi, H., Ishii, T., Asai, S., Hirata, S., Ikeda, K., Suzuki, K., Kato, N., & Kaneko, Y. (2025). Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study). PLOS One. https://doi.org/10.1371/journal.pone.0322621
Vancouver
Akiyama M, Hidaka T, Kaneko M, Ito S, Taguchi H, Ishii T, et al. Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study). PLOS One. 2025. doi:10.1371/journal.pone.0322621
BibTeX
@article{Akiyama2025,
author = {Akiyama, Mitsuhiro and Hidaka, Toshihiko and Kaneko, Motohide and Ito, Satoshi and Taguchi, Hiroaki and Ishii, Tomonori and Asai, Shuji and Hirata, Shintaro and Ikeda, Kei and Suzuki, Katsuya and Kato, Naoki and Kaneko, Yuko},
title = {Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study)},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0322621}
}
EUVIMED